Evidence map›Paper›PMID 36803541›Full record

ArticleMalaria journal2023

Assessment of artemisinin tolerance in Plasmodium falciparum clinical isolates in children with uncomplicated malaria in Ghana.

Samuel Yao Ahorhorlu, Neils Ben Quashie, Rasmus Weisel Jensen, William Kudzi, Edmund Tetteh Nartey, Nancy Odurowah Duah-Quashie, Felix Zoiku, Bartholomew Dzudzor, Christian William Wang, Helle Hansson and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Malaria journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. DifferentialMicrobiology spectrum · 2025
    Article
  4. Article
  5. Day 3 parasitemia andmedRxiv : the preprint server for health sciences · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Samuel Yao AhorhorluCentre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, University of Ghana, P.O. Box 4236, Accra, Ghana.
Neils Ben QuashieCentre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, University of Ghana, P.O. Box 4236, Accra, Ghana.
Rasmus Weisel JensenCentre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
William KudziCentre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, University of Ghana, P.O. Box 4236, Accra, Ghana.
Edmund Tetteh NarteyCentre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, University of Ghana, P.O. Box 4236, Accra, Ghana.
Nancy Odurowah Duah-QuashieDepartment of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Felix ZoikuDepartment of Epidemiology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Bartholomew DzudzorDepartment of Medical Biochemistry, University of Ghana Medical School, University of Ghana, Accra, Ghana.
Christian William WangCentre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Helle HanssonCentre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Michael AlifrangisCentre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
George Obeng AdjeiCentre for Tropical Clinical Pharmacology and Therapeutics, University of Ghana Medical School, University of Ghana, P.O. Box 4236, Accra, Ghana. gadjei@ug.edu.gh.
University of Ghana · GHUniversity of Copenhagen · DKCopenhagen University Hospital · DKRigshospitalet · DK

Funding

Danish Government Building Stronger Universities in Developing Countries (BSU II project)
6 · The paper itself

Abstract

backgroundArtemisinin-based combination therapy (ACT) is the first-line treatment for uncomplicated malaria in Ghana. Artemisinin (ART) tolerance in Plasmodium falciparum has arisen in Southeast Asia and recently, in parts of East Africa. This is ascribed to the survival of ring-stage parasites post treatment. The present study sought to assess and characterize correlates of potential ART tolerance based on post-treatment parasite clearance, ex vivo and in vitro drug sensitivity, and molecular markers of drug resistance in P. falciparum isolates from children with uncomplicated malaria in Ghana.

methodsSix months to fourteen years old children presenting with acute uncomplicated malaria (n = 115) were enrolled in two hospitals and a Health Centre in Ghana's Greater Accra region and treated with artemether-lumefantrine (AL) according to body weight. Pre- and post-treatment parasitaemia (day 0 and day 3) was confirmed by microscopy. The ex vivo ring-stage survival assay (RSA) was used to detect percent ring survival while the 72 h SYBR Green I assay was used to measure the 50% inhibition concentration (IC

resultsOf the total of 115 participants, 85 were successfully followed up on day 3 post-treatment and 2/85 (2.4%) had parasitaemia. The IC

conclusionsThe observed low proportion of participants with day-3 post-treatment parasitaemia is consistent with rapid ART clearance. However, the increased rates of survival observed in the ex vivo RSA against DHA, maybe a pointer of an early start of ART tolerance. Furthermore, the role of two novel mutations in PfK13 and Pfcoronin genes, harboured by the two RSA positive isolates that had high ring survival in the present study, remains to be elucidated.

Indexed as

AntimalarialsArtemisininsMalariaMalaria, FalciparumArtemetherArtemether, Lumefantrine Drug CombinationChildDrug CombinationsDrug ToleranceGhanaHumansLumefantrinePlasmodium falciparumAntimalarialsArtemetherArtemether, Lumefantrine Drug CombinationartemisininArtemisininsartenimolDrug CombinationsLumefantrineArtemisinin toleranceEx vivo ring-stage survival assayGhanaKelch 13PfcoroninPlasmodium falciparumUncomplicated Malaria

Identifiers

PMID36803541
PMCPMC9938975
OpenAlexW4321352148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.